Gabelli Funds’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-369,860
| Closed | -$817K | – | 1168 |
|
|
2023
Q2 | $817K | Buy |
369,860
+335,360
| +972% | +$696K | 0.01% | 837 |
|
|
2023
Q1 | $87.6K | Sell |
34,500
-4,000
| -10% | -$7.9K | ﹤0.01% | 1067 |
|
|
2022
Q4 | $72K | Sell |
38,500
-9,000
| -19% | -$22.4K | ﹤0.01% | 1117 |
|
|
2022
Q3 | $122K | Hold |
47,500
| – | – | ﹤0.01% | 1194 |
|
|
2022
Q2 | $92K | Sell |
47,500
-500
| -1% | -$1.09K | ﹤0.01% | 1246 |
|
|
2022
Q1 | $143K | Hold |
48,000
| – | – | ﹤0.01% | 1269 |
|
|
2021
Q4 | $216K | Buy |
48,000
+5,000
| +12% | +$23.7K | ﹤0.01% | 1252 |
|
|
2021
Q3 | $209K | Buy |
43,000
+33,000
| +330% | +$182K | ﹤0.01% | 1242 |
|
|
2021
Q2 | $68K | Sell |
10,000
-4,600
| -32% | -$37.2K | ﹤0.01% | 1294 |
|
|
2021
Q1 | $103K | Buy |
14,600
+1,000
| +7% | +$7.2K | ﹤0.01% | 1268 |
|
|
2020
Q4 | $85K | Buy |
13,600
+2,000
| +17% | +$11.8K | ﹤0.01% | 1175 |
|
|
2020
Q3 | $63K | Hold |
11,600
| – | – | ﹤0.01% | 1095 |
|
|
2020
Q2 | $61K | Sell |
11,600
-600
| -5% | -$2.67K | ﹤0.01% | 1031 |
|
|
2020
Q1 | $38K | Hold |
12,200
| – | – | ﹤0.01% | 1045 |
|
|
2019
Q4 | $49K | Sell |
12,200
-31,300
| -72% | -$109K | ﹤0.01% | 1073 |
|
|
2019
Q3 | $188K | Sell |
43,500
-5,500
| -11% | -$22K | ﹤0.01% | 1052 |
|
|
2019
Q2 | $196K | Sell |
49,000
-5,000
| -9% | -$23.8K | ﹤0.01% | 1083 |
|
|
2019
Q1 | $289K | Hold |
54,000
| – | – | ﹤0.01% | 1045 |
|
|
2018
Q4 | $277K | Buy |
+54,000
| New | +$410K | ﹤0.01% | 1050 |
|
Gabelli Funds's PRTK Position: Q3 2023 in Review
Gabelli Funds sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2023, closing a stake of 369,860 shares — an estimated $817K sold.
Gabelli Funds first reported a position in PRTK in Q4 2018 and held it in 19 quarters. The position peaked at $817K in Q2 2023. 0 funds tracked by Wall St. Rank hold PRTK as of Q3 2023.
- Gabelli Funds reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
- Gabelli Funds sold 369,860 Paratek Pharmaceuticals, Inc. shares in Q3 2023, an estimated $817K.
- Gabelli Funds first reported a position in Paratek Pharmaceuticals, Inc. in Q4 2018 and held it in 19 quarters.
- Gabelli Funds's Paratek Pharmaceuticals, Inc. position peaked at $817K in Q2 2023.
- 0 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2023.
Based on Gabelli Funds's 13F filing for Q3 2023, filed 8 Nov 2023.